Maxim Group Issues Positive Forecast for Alterity Therapeutics (NASDAQ:ATHE) Stock Price

Alterity Therapeutics (NASDAQ:ATHE) had its price target raised by Maxim Group from $8.00 to $12.00 in a report published on Thursday,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Alterity Therapeutics Stock Up 57.0 %

Shares of ATHE opened at $4.57 on Thursday. Alterity Therapeutics has a twelve month low of $1.00 and a twelve month high of $5.87. The stock’s fifty day simple moving average is $2.71 and its 200 day simple moving average is $1.81.

Institutional Trading of Alterity Therapeutics

A hedge fund recently raised its stake in Alterity Therapeutics stock. HB Wealth Management LLC grew its holdings in shares of Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,883 shares of the company’s stock after buying an additional 8,100 shares during the quarter. HB Wealth Management LLC owned 0.44% of Alterity Therapeutics worth $110,000 at the end of the most recent quarter. 2.14% of the stock is currently owned by institutional investors and hedge funds.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.